91 related articles for article (PubMed ID: 21698408)
1. Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
Kawaguchi K; Ishiguro H; Morita S; Nakamura S; Ohno S; Masuda N; Iwata H; Aogi K; Kuroi K; Toi M;
Breast Cancer Res Treat; 2011 Nov; 130(2):627-34. PubMed ID: 21698408
[TBL] [Abstract][Full Text] [Related]
2. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
3. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
Freyer G; Campone M; Peron J; Facchini T; Terret C; Berdah JF; Jacquin JP; Coeffic D; Hilaire Pde S; Falandry C
Crit Rev Oncol Hematol; 2011 Dec; 80(3):466-73. PubMed ID: 21565521
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
Hsu YH; Shen WC; Wang CH; Lin YF; Chen SC
Eur J Oncol Nurs; 2019 Dec; 43():101670. PubMed ID: 31586645
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
8. [Administration Order of FEC-DOC in Breast Cancer Adjuvant Chemotherapy Has an Effect on Toxicity].
Miyaki T; Tsujimura H; Nakamura R; Okubo Y; Kumagai K; Yamamoto N
Gan To Kagaku Ryoho; 2015 Sep; 42(9):1081-5. PubMed ID: 26469164
[TBL] [Abstract][Full Text] [Related]
9. Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.
Thiery-Vuillemin A; Llombart-Cussac A; Chaigneau L; Villanueva C; Bazan F; Montcuquet P; Maisonnette-Escot Y; Sautiere JL; Algros MP; Pivot X
Breast; 2011 Feb; 20(1):46-9. PubMed ID: 20692157
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
14. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Hilli J; Sailas L; Jyrkkiö S; Pyrhönen S; Laine K
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
16. Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group.
Fraser J; Steele N; Al Zaman A; Yule A
Eur J Cancer; 2011 Jan; 47(2):215-20. PubMed ID: 21094038
[TBL] [Abstract][Full Text] [Related]
17. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
[TBL] [Abstract][Full Text] [Related]
19. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.
Jacobs C; Hutton B; Mazzarello S; Smith S; Joy A; Amir E; Ibrahim MF; Gregario N; Daigle K; Eggert L; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3269-75. PubMed ID: 25933700
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
Tham YL; Gomez LF; Mohsin S; Gutierrez MC; Weiss H; Hilsenbeck SG; Elledge RM; Chamness GC; Osborne CK; Allred DC; Chang JC
Breast Cancer Res Treat; 2005 Dec; 94(3):279-84. PubMed ID: 16261403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
